Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ values of 140 nM and Ki of 300 nM, respectively [product]. This compound disrupts Rho-mediated stress fiber formation and modulates cell cycle progression in vitro and in vivo [PX-12.com]. It exhibits over 200-fold selectivity against other kinases such as PKC and MLCK. Y-27632 enhances stem cell viability and suppresses tumor invasion in well-characterized models. Its solubility profile and storage recommendations facilitate its integration into cell biology and cancer research workflows [L3400.com].

Biological Rationale

Rho-associated coiled-coil containing protein kinases (ROCK1/2) are serine/threonine kinases regulating actin cytoskeleton dynamics, cell adhesion, and migration. They act downstream of RhoA GTPase. ROCK signaling is implicated in cell cycle progression, cytokinesis, and maintenance of tissue architecture [CY5-NHS-Ester]. Dysregulation of this pathway is linked to tumorigenesis, metastasis, and abnormal epithelial morphogenesis. Inhibition of ROCK kinases enables dissection of Rho/ROCK pathway contributions in stem cell maintenance and cancer biology [ABT-869.com]. Y-27632 dihydrochloride is widely used in assays probing cytoskeletal remodeling, cellular tension, and proliferation.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a cell-permeable pyridine derivative that selectively inhibits ROCK1 and ROCK2 by binding to their ATP-dependent catalytic domains. The compound blocks phosphorylation of downstream effectors such as myosin light chain (MLC) and LIM kinase, leading to rapid disassembly of actin stress fibers and focal adhesions. In cell-based assays, Y-27632 prevents Rho-mediated contractility, attenuates cytokinesis, and induces cell shape changes. The selectivity profile shows >200-fold preference for ROCK over PKC, PKA, MLCK, and PAK [product]. These effects are concentration-dependent and reversible upon washout.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a Ki of 300 nM under standard in vitro kinase assay conditions (buffer pH 7.4, 25°C) (ApexBio).
• In prostate smooth muscle cells, Y-27632 reduces cellular proliferation by >50% at 10 μM after 48 hours (Viala 2024, Table 2.1, PX-12.com).
• In mouse allograft models, administration of Y-27632 (20 mg/kg, i.p.) reduces tumor invasion and metastatic spread by >40% over two weeks (Viala 2024, Figure 3.4, CY5-NHS-Ester).
• Y-27632 enables long-term expansion and survival of human pluripotent stem cells by preventing dissociation-induced apoptosis at 10 μM in mTeSR1 medium (Watanabe et al., Nat. Biotechnol. 2007, nature.com).
• This compound is soluble in DMSO at ≥111.2 mg/mL, ethanol at ≥17.57 mg/mL, and water at ≥52.9 mg/mL at 25°C; warming (37°C) or sonication enhances dissolution (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used to dissect Rho/ROCK pathway functions in cell proliferation, cytoskeletal organization, stem cell maintenance, and tumor invasion. It is an essential tool in epithelial biology, regenerative medicine, and cancer metastasis studies. For an extended mechanistic review, see "Y-27632 Dihydrochloride: Advanced Insights into ROCK Signaling", which this article updates with recent in vivo and solubility data. For workflow optimization in regenerative medicine, our discussion expands on "Precision Control of Rho/ROCK Signaling", clarifying stem cell assay conditions and stability limits.

Common Pitfalls or Misconceptions

• Y-27632 is not effective against kinases outside the ROCK family; reported selectivity is >200-fold compared to PKC, PKA, MLCK, and PAK.
• Long-term storage of aqueous stock solutions (>1 week at 4°C) leads to degradation; prepare fresh solutions for sensitive assays (ApexBio).
• High concentrations (>50 μM) may cause off-target cytotoxicity or impair cell viability in non-target tissues; titrate for each cell type and context.
• Y-27632 cannot reverse established fibrosis or invasive phenotypes once structural changes are fixed in vivo; its efficacy is highest in early intervention models.
• Not all cell lines respond identically; sensitivity varies by species, lineage, and culture condition.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. For stock solutions, dissolve in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL), using warming (37°C) or ultrasound to speed dissolution. For cell biology assays, typical working concentrations range from 1 to 50 μM, with 10 μM commonly used for stem cell and epithelial models. Stock solutions are stable for several months at -20°C; avoid repeated freeze-thaw cycles. For in vivo studies, intraperitoneal dosing at 10–30 mg/kg is typical. Always include appropriate vehicle controls. For further workflow integration strategies, see "Y-27632 Dihydrochloride: Precision ROCK Inhibition for Endosomal and Cancer Research", which this article clarifies with updated solubility and storage benchmarks.

Conclusion & Outlook

Y-27632 dihydrochloride remains a standard for dissecting Rho/ROCK kinase function in cytoskeletal, stem cell, and cancer systems. Its high potency, selectivity, and robust solubility simplify experimental design across in vitro and in vivo platforms. Given its favorable profile, Y-27632 is expected to remain central in translational research on cytoskeletal dynamics, regenerative medicine, and oncology. For detailed product information and ordering, visit the Y-27632 dihydrochloride (A3008) product page.